PSMA放射性配体治疗用于前列腺癌以外实体瘤的背景、机遇、挑战与首批临床报告
综述总结PSMA在前列腺癌以外实体瘤中的表达及PSMA PET/CT显像的(前)临床数据,涵盖唾液腺癌、胶质母细胞瘤、甲状腺癌、肾细胞癌、肝细胞癌、肺癌和乳腺癌。文中描述非前列腺癌患者接受PSMA放射性配体治疗的首批临床报告,并讨论更广泛临床实施的机遇与挑战。
要点
- PSMA除高表达于前列腺癌外,也在多种实体瘤尤其肿瘤相关新生血管中不同程度表达。
- 综述汇总唾液腺癌、胶质母细胞瘤、甲状腺癌、肾细胞癌、肝细胞癌、肺癌和乳腺癌的PSMA免疫组化与PET/CT数据。
- 文中描述非前列腺癌患者接受PSMA放射性配体治疗的首批临床报告。
核心结论
- PSMA放射性配体治疗在前列腺癌中显示良好结果且耐受性较好,基于其他实体瘤的PSMA表达,有望探索用于前列腺癌以外实体瘤。
研究设计与样本
- 综述聚焦唾液腺癌、胶质母细胞瘤、甲状腺癌、肾细胞癌、肝细胞癌、肺癌和乳腺癌,汇总PSMA免疫组化与PSMA PET/CT的(前)临床数据及非前列腺癌患者PSMA放射性配体治疗的首批临床报告。
主要发现
- PSMA在前列腺癌细胞中高度过表达,在其他恶性肿瘤尤其是肿瘤相关新生血管中也有不同程度表达。
- 综述提供了上述实体瘤PSMA免疫组化和PSMA PET/CT显像数据的概览与总结。
临床怎么用
- 综述为评估PSMA放射性配体治疗在前列腺癌以外实体瘤中的临床应用前景提供背景与首批临床报告参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the past decade, a growing body of literature has reported promising results for prostate-specific membrane antigen (PSMA)-targeted radionuclide imaging and therapy in prostate cancer. First clinical studies evaluating the efficacy of [177Lu]Lu-PSMA radioligand therapy (PSMA-RLT) demonstrated favorable results in prostate cancer patients. [177Lu]Lu-PSMA is generally well tolerated due to its limited side effects. While PSMA is highly overexpressed in prostate cancer cells, varying degrees of PSMA expression have been reported in other malignancies as well, particularly in the tumor-associated neovasculature. Hence, it is anticipated that PSMA-RLT could be explored for other solid cancers. Here, we describe the current knowledge of PSMA expression in other solid cancers and define a perspective towards broader clinical implementation of PSMA-RLT. This review focuses specifically on salivary gland cancer, glioblastoma, thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, lung cancer, and breast cancer. An overview of the (pre)clinical data on PSMA immunohistochemistry and PSMA PET/CT imaging is provided and summarized. Furthermore, the first clinical reports of non-prostate cancer patients treated with PSMA-RLT are described.
引用
- Uijen MJM, Derks YHW, Merkx RIJ, et al. PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports. Eur J Nucl Med Mol Imaging. 2021. PMID: 34120192. doi:10.1007/s00259-021-05433-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。